Back to Search
Start Over
Dose Escalation Study of Epirubicin and Docetaxel in Patients with Advanced or Recurrent Breast Cancer
- Source :
- Chemotherapy. 54:379-385
- Publication Year :
- 2008
- Publisher :
- S. Karger AG, 2008.
-
Abstract
- Background: Anthracyclines and taxanes are major cytotoxic drugs against breast cancer. To develop a combination of epirubicin (EPI) and docetaxel (DTX) in Japan, dose escalation and pharmacokinetic studies were performed in patients with advanced or recurrent breast cancer. Methods: Twenty patients received EPI (40, 50 or 60 mg/m2) as 5-min intravenous infusion, followed by DTX infusion (50 or 60 mg/m2) over 1 h in cohorts of 3–6 patients. The maximum tolerated dose (MTD) was defined during the first cycle when more than 2 of 3 or 3 of 6 patients suffered a dose-limiting toxicity (DLT). The DLT was based on febrile neutropenia (FN), prolonged neutropenia, thrombocytopenia and grade 3–4 nonhematological toxicity during the first cycle. Plasma sampling was performed to assess the pharmacokinetic study of these drugs. Results: The second level (EPI/DTX 50/50 mg/m2) was found to be a maximum tolerated dose because of a short duration of FN with no distress. Subsequently, the protocol was modified to permit a new DLT definition including FN lasting for more than 72 h. At the following levels of EPI/DTX 50/50, 50/60 or 60/60 mg/m2, the dose escalation study revealed a high incidence of grade 4 neutropenia (100%) and FN (67%), which did not reach DLT. However, the safety committee decided not to go further because of too high an incidence of FN lasting 3 days, although a little less than 72 h. The pharmacokinetic study with a combination of EPI and DTX showed comparable blood levels of DTX and EPI in relation to those seen when given alone. Conclusion: For further evaluation, the recommended dose and schedule of this combination is EPI 60 mg/m2 and DTX 60 mg/m2, given every 3 weeks to patients without prior chemotherapy and EPI 50 mg/m2 and DTX 50 mg/m2 given to patients with prior chemotherapy, respectively. The pharmacokinetic study indicates no interaction between EPI and DTX.
- Subjects :
- Adult
medicine.medical_specialty
medicine.medical_treatment
Urology
Breast Neoplasms
Docetaxel
Pharmacology
Neutropenia
Breast cancer
Pharmacokinetics
Antineoplastic Combined Chemotherapy Protocols
Drug Discovery
medicine
Humans
Pharmacology (medical)
Aged
Epirubicin
Neoplasm Staging
Chemotherapy
Dose-Response Relationship, Drug
business.industry
General Medicine
Middle Aged
medicine.disease
Infectious Diseases
Oncology
Toxicity
Female
Taxoids
Neoplasm Recurrence, Local
business
Febrile neutropenia
medicine.drug
Subjects
Details
- ISSN :
- 14219794 and 00093157
- Volume :
- 54
- Database :
- OpenAIRE
- Journal :
- Chemotherapy
- Accession number :
- edsair.doi.dedup.....db3c0e0197a9f5a5922706d6e690245d